Ivadal

Zolpidem, the active ingredient in Ivadal, is a non‑benzodiazepine hypnotic presented as an oral tablet for oral use. It is prescribed to adults who have difficulty initiating sleep, providing a short‑term solution for insomnia. It is indicated for short‑term management of sleep onset difficulties in patients without underlying psychiatric disorders.

GNH USA supplies Ivadal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Zolpidem acts on the central nervous system to facilitate sleep onset in patients with insomnia.

Insomnia (difficulty initiating sleep): helps patients fall asleep more quickly and improves sleep latency. Short‑term insomnia: provides a temporary aid to establish a regular sleep pattern. Sleep onset disorder: reduces the time needed to transition from wakefulness to sleep.

Zolpidem may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dizziness - Headache - Dry mouth

Serious or Rare Side Effects: - Complex sleep behaviors (e.g., sleepwalking, driving while asleep) - Allergic reactions (rash, swelling, anaphylaxis) - Depression or suicidal thoughts

When prescribing Zolpidem, clinicians should consider several safety precautions to minimize risks.

Assess sleep history: confirm diagnosis of insomnia and evaluate duration of symptoms. Avoid alcohol and CNS depressants: concurrent use can enhance sedative effects. Monitor for complex sleep behaviors: advise patients to report unusual activities during sleep. Use the lowest effective dose: limit exposure and reduce potential adverse effects. Advise against operating machinery: patients should refrain from driving or using heavy machinery until they know how the drug affects them. Store at room temperature: keep tablets in the original container, protect from moisture and light.

Zolpidem can interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase zolpidem plasma levels. - Opioids (e.g., morphine, oxycodone): combined CNS depression can be dangerous. - Alcohol: additive sedative effect heightens risk of respiratory depression. - Other hypnotics or sedatives (e.g., benzodiazepines, barbiturates): may cause excessive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., SSRIs, SNRIs): may alter sleep architecture. - Antihistamines (e.g., diphenhydramine): additive drowsiness.